Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health

S. Delgado-Aros, H. J. Chial, F. Cremonini, I. Ferber, S. McKinzie, D. D. Burton, Michael Camilleri

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Aim: To evaluate the effect of single administrations of asimadoline, a κ-opioid agonist, on satiation volume, postprandial symptoms and gastric volumes. Methods: Healthy subjects received oral placebo, or 0.5 or 1.5 mg asimadoline in a randomized, double-blind fashion 1 h prior to testing. We assessed effects on the volume of Ensure to achieve full satiation and postprandial symptoms 30 min after meal, and on gastric volume (fasting and postprandial) measured by 99mTc-single photon emission tomography (SPECT) imaging. Results: Thirteen healthy subjects were studied in each treatment arm. Compared to placebo, asimadoline 0.5 mg decreased postprandial fullness (P = 0.027) without affecting the volume ingested at full satiation (P = 0.6). Asimadoline 1.5 mg decreased satiation during meal, allowing increased satiation volumes (P = 0.008) and tended to decrease postprandial fullness (P = 0.067), despite higher volumes ingested. There was a significant treatment-gender interaction in the effect of asimadoline on gastric volumes (P <0.05). Asimadoline 0.5 mg (not 1.5 mg) increased fasting (P = 0.047) and postprandial (P = 0.009) gastric volumes in females but decreased fasting volumes in males (P = 0.008). The effect of asimadoline on gastric volume did not explain the effect observed on satiation volume (P = 0.371) or postprandial fullness (P = 0.399). Conclusion: A single oral administration of asimadoline decreases satiation and postprandial fullness in humans independently of its effects on gastric volume.

Original languageEnglish (US)
Pages (from-to)507-514
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume18
Issue number5
DOIs
StatePublished - Sep 1 2003

Fingerprint

Satiation
Opioid Analgesics
Stomach
Health
Fasting
Meals
Healthy Volunteers
Placebos
asimadoline
Single-Photon Emission-Computed Tomography
Photons
Oral Administration
Tomography

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health. / Delgado-Aros, S.; Chial, H. J.; Cremonini, F.; Ferber, I.; McKinzie, S.; Burton, D. D.; Camilleri, Michael.

In: Alimentary Pharmacology and Therapeutics, Vol. 18, No. 5, 01.09.2003, p. 507-514.

Research output: Contribution to journalArticle

Delgado-Aros, S. ; Chial, H. J. ; Cremonini, F. ; Ferber, I. ; McKinzie, S. ; Burton, D. D. ; Camilleri, Michael. / Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health. In: Alimentary Pharmacology and Therapeutics. 2003 ; Vol. 18, No. 5. pp. 507-514.
@article{76731e1f89534f17a35fabd6b22d49a9,
title = "Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health",
abstract = "Aim: To evaluate the effect of single administrations of asimadoline, a κ-opioid agonist, on satiation volume, postprandial symptoms and gastric volumes. Methods: Healthy subjects received oral placebo, or 0.5 or 1.5 mg asimadoline in a randomized, double-blind fashion 1 h prior to testing. We assessed effects on the volume of Ensure to achieve full satiation and postprandial symptoms 30 min after meal, and on gastric volume (fasting and postprandial) measured by 99mTc-single photon emission tomography (SPECT) imaging. Results: Thirteen healthy subjects were studied in each treatment arm. Compared to placebo, asimadoline 0.5 mg decreased postprandial fullness (P = 0.027) without affecting the volume ingested at full satiation (P = 0.6). Asimadoline 1.5 mg decreased satiation during meal, allowing increased satiation volumes (P = 0.008) and tended to decrease postprandial fullness (P = 0.067), despite higher volumes ingested. There was a significant treatment-gender interaction in the effect of asimadoline on gastric volumes (P <0.05). Asimadoline 0.5 mg (not 1.5 mg) increased fasting (P = 0.047) and postprandial (P = 0.009) gastric volumes in females but decreased fasting volumes in males (P = 0.008). The effect of asimadoline on gastric volume did not explain the effect observed on satiation volume (P = 0.371) or postprandial fullness (P = 0.399). Conclusion: A single oral administration of asimadoline decreases satiation and postprandial fullness in humans independently of its effects on gastric volume.",
author = "S. Delgado-Aros and Chial, {H. J.} and F. Cremonini and I. Ferber and S. McKinzie and Burton, {D. D.} and Michael Camilleri",
year = "2003",
month = "9",
day = "1",
doi = "10.1046/j.1365-2036.2003.01670.x",
language = "English (US)",
volume = "18",
pages = "507--514",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health

AU - Delgado-Aros, S.

AU - Chial, H. J.

AU - Cremonini, F.

AU - Ferber, I.

AU - McKinzie, S.

AU - Burton, D. D.

AU - Camilleri, Michael

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Aim: To evaluate the effect of single administrations of asimadoline, a κ-opioid agonist, on satiation volume, postprandial symptoms and gastric volumes. Methods: Healthy subjects received oral placebo, or 0.5 or 1.5 mg asimadoline in a randomized, double-blind fashion 1 h prior to testing. We assessed effects on the volume of Ensure to achieve full satiation and postprandial symptoms 30 min after meal, and on gastric volume (fasting and postprandial) measured by 99mTc-single photon emission tomography (SPECT) imaging. Results: Thirteen healthy subjects were studied in each treatment arm. Compared to placebo, asimadoline 0.5 mg decreased postprandial fullness (P = 0.027) without affecting the volume ingested at full satiation (P = 0.6). Asimadoline 1.5 mg decreased satiation during meal, allowing increased satiation volumes (P = 0.008) and tended to decrease postprandial fullness (P = 0.067), despite higher volumes ingested. There was a significant treatment-gender interaction in the effect of asimadoline on gastric volumes (P <0.05). Asimadoline 0.5 mg (not 1.5 mg) increased fasting (P = 0.047) and postprandial (P = 0.009) gastric volumes in females but decreased fasting volumes in males (P = 0.008). The effect of asimadoline on gastric volume did not explain the effect observed on satiation volume (P = 0.371) or postprandial fullness (P = 0.399). Conclusion: A single oral administration of asimadoline decreases satiation and postprandial fullness in humans independently of its effects on gastric volume.

AB - Aim: To evaluate the effect of single administrations of asimadoline, a κ-opioid agonist, on satiation volume, postprandial symptoms and gastric volumes. Methods: Healthy subjects received oral placebo, or 0.5 or 1.5 mg asimadoline in a randomized, double-blind fashion 1 h prior to testing. We assessed effects on the volume of Ensure to achieve full satiation and postprandial symptoms 30 min after meal, and on gastric volume (fasting and postprandial) measured by 99mTc-single photon emission tomography (SPECT) imaging. Results: Thirteen healthy subjects were studied in each treatment arm. Compared to placebo, asimadoline 0.5 mg decreased postprandial fullness (P = 0.027) without affecting the volume ingested at full satiation (P = 0.6). Asimadoline 1.5 mg decreased satiation during meal, allowing increased satiation volumes (P = 0.008) and tended to decrease postprandial fullness (P = 0.067), despite higher volumes ingested. There was a significant treatment-gender interaction in the effect of asimadoline on gastric volumes (P <0.05). Asimadoline 0.5 mg (not 1.5 mg) increased fasting (P = 0.047) and postprandial (P = 0.009) gastric volumes in females but decreased fasting volumes in males (P = 0.008). The effect of asimadoline on gastric volume did not explain the effect observed on satiation volume (P = 0.371) or postprandial fullness (P = 0.399). Conclusion: A single oral administration of asimadoline decreases satiation and postprandial fullness in humans independently of its effects on gastric volume.

UR - http://www.scopus.com/inward/record.url?scp=0141517479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141517479&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2003.01670.x

DO - 10.1046/j.1365-2036.2003.01670.x

M3 - Article

C2 - 12950423

AN - SCOPUS:0141517479

VL - 18

SP - 507

EP - 514

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -